Observer variability in a phase II trial - assessing consistency in RECIST application.
about
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials.Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma.
P2860
Observer variability in a phase II trial - assessing consistency in RECIST application.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Observer variability in a phase II trial - assessing consistency in RECIST application.
@en
Observer variability in a phase II trial - assessing consistency in RECIST application.
@nl
type
label
Observer variability in a phase II trial - assessing consistency in RECIST application.
@en
Observer variability in a phase II trial - assessing consistency in RECIST application.
@nl
prefLabel
Observer variability in a phase II trial - assessing consistency in RECIST application.
@en
Observer variability in a phase II trial - assessing consistency in RECIST application.
@nl
P2093
P2860
P1433
P1476
Observer variability in a phase II trial - assessing consistency in RECIST application.
@en
P2093
Benny Vittrup Jensen
Dorte Nielsen
Helle Hjorth Johannesen
Helle Westergren Hendel
Kristin Skougaard
Mark James Dusgaard McCullagh
P2860
P304
P356
10.3109/0284186X.2012.667149
P577
2012-03-21T00:00:00Z